{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/CDC"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"CDC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CDC\",,,,,undefined,":{"symbol":"CDC","market":"US","secType":"STK","nameCN":"VictoryShares US EQ Income Enhanced Volatility Wtd ETF","latestPrice":61.31,"timestamp":1744920000000,"preClose":60.49,"halted":0,"volume":14149,"hourTrading":{"tag":"盘后","latestPrice":61.23,"preClose":61.31,"latestTime":"16:08 EDT","volume":9,"amount":545.89,"timestamp":1744920488539},"delay":0,"floatShares":11700000,"shares":11700000,"eps":0,"marketStatus":"Market Closed","change":0.82,"latestTime":"04-17 16:00:00 EDT","open":60.57,"high":61.79,"low":60.57,"amount":869493.61888,"amplitude":0.020169,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745222400000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":60.49,"sharesOutstanding":11700000,"nav":61.232657,"aum":716422590,"bidAskSpread":0.000877,"postHourTrading":{"tag":"盘后","latestPrice":61.23,"preClose":61.31,"latestTime":"16:08 EDT","volume":9,"amount":545.89,"timestamp":1744920488539},"volumeRatio":0.6806265082874517,"impliedVol":0.0247,"impliedVolPercentile":0.1355},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CDC\",,,,,undefined,":{"symbol":"CDC","floatShares":11700000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.6806265082874517,"shares":11700000,"dividePrice":2.06991,"high":61.79,"amplitude":0.020169,"preClose":60.49,"low":60.57,"week52Low":56.63,"pbRate":"--","week52High":67.7599,"institutionHeld":0,"latestPrice":61.31,"eps":0,"divideRate":0.033761,"volume":14149,"delay":0,"ttmEps":0,"open":60.57,"prevYearClose":62.58,"prevWeekClose":60.33,"prevMonthClose":65.72,"prevQuarterClose":65.72,"fiveDayClose":59.73,"twentyDayClose":64.95,"sixtyDayClose":63.97},"@#url:\"https://hq.skytigris.cn/market/plate/belongs/CDC\",params:#limit:6,delay:false,,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CDC\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2528023465","title":"GE2025: SPP launches manifesto, proposes distributing government surpluses as CDC vouchers","url":"https://stock-news.laohu8.com/highlight/detail?id=2528023465","media":"businesstimes","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528023465?lang=en_us&edition=fundamental","pubTime":"2025-04-19 01:55","pubTimestamp":1744998957,"startTime":"0","endTime":"0","summary":"[SINGAPORE] The Singapore People’s Party (SPP) has launched its manifesto ahead of the 2025 General Election on May 3.  ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"bustime_highlight","url":"https://www.businesstimes.com.sg/singapore/ge2025-spp-launches-manifesto-proposes-distributing-government-surpluses-cdc-vouchers","rn_cache_url":null,"customStyle":"","selectors":"body","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.businesstimes.com.sg/singapore/ge2025-spp-launches-manifesto-proposes-distributing-government-surpluses-cdc-vouchers","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"bustime_highlight","symbols":["CDC"],"gpt_icon":0},{"id":"2528722823","title":"Pfizer (NYSE:PFE) Gets CDC Recommendation to Expand ABRYSVO Vaccine Use for RSV Prevention","url":"https://stock-news.laohu8.com/highlight/detail?id=2528722823","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528722823?lang=en_us&edition=fundamental","pubTime":"2025-04-18 01:25","pubTimestamp":1744910734,"startTime":"0","endTime":"0","summary":"Pfizer recently received a CDC recommendation for wider use of its RSV vaccine, ABRYSVO, in adults aged 50-59 at increased risk. Despite this positive development, Pfizer's shares saw a 2% decline over the past week. This move is in line with broader market trends, as the market dropped by 3% during the same period. The company's decision to halt development of Danuglipron, an oral weight loss drug, due to safety concerns, may have also added weight to the downward pressure on its shares, amid wider concerns impacting the healthcare sector and investor sentiment surrounding safety in drug development.Pfizer has 3 possible red flags  we think you should know about.The recent CDC recommendation for Pfizer's RSV vaccine, ABRYSVO, is a promising development that could positively impact the company's revenue and earnings forecasts; however, the decision to halt development of the Danuglipron weight loss drug amplifies concerns over safety in drug development. This mix of news, coupled with ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pfizer-nyse-pfe-gets-cdc-172534992.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4592","IE00BLSP4239.USD","SG9999013999.USD","LU0234572021.USD","NYSE","SG9999011175.SGD","IE00B19Z3581.USD","BK4588","LU0456855351.SGD","LU0306806265.USD","BK4534","LU1894683264.USD","SG9999003800.SGD","SGXZ57979304.SGD","LU0321505439.SGD","BK4581","IE0002270589.USD","LU0225284248.USD","IE00B19Z3B42.SGD","BK4550","LU0985481810.HKD","PFE","SG9999001176.USD","IE00BBT3K403.USD","LU0225771236.USD","IE000M9KFDE8.USD","LU0122379950.USD","LU0170899867.USD","LU1066051498.USD","LU0058720904.USD","BK4599","BK4585","LU1023059063.AUD","SG9999001176.SGD","CDC","IE00BLSP4452.SGD","LU0289739699.SGD","SG9999002224.SGD","SG9999002232.USD","LU0306807586.USD","BK4568","LU0868494617.USD","BK4533","LU1894683348.USD","LU0321505868.SGD","LU1883839398.USD","BK4007","LU1057294990.SGD","LU1066053197.SGD"],"gpt_icon":1},{"id":"2528723115","title":"Eli Lilly's weight loss pill could be just as good as Ozempic — and the stock soars","url":"https://stock-news.laohu8.com/highlight/detail?id=2528723115","media":"Quartz","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528723115?lang=en_us&edition=fundamental","pubTime":"2025-04-17 23:20","pubTimestamp":1744903245,"startTime":"0","endTime":"0","summary":"The first GLP-1 pill could be in medicine cabinets sooner than expected.Eli Lilly  announced Thursday that its daily obesity pill, orforglipron, met company goals in the first of several late-stage trials — helping patients with Type 2 diabetes lower their blood sugar while causing weight loss. The results were comparable with other GLP-1 injections on the market, such as Ozempic and Mounjaro.Orforglipron could give Lilly a key advantage over other pharmaceutical giants in the GLP-1 realm. Lilly’s stock was up 11% in premarket trading. Novo Nordisk , which makes Ozempic, was down 6%.The results are pivotal: While the GLP-1 class of medication has become a blockbuster on the market , they’re expensive, must be injected, and need to be kept refrigerated. A pill version would be a more convenient option that could be much more widely used.The study measured weight loss as a secondary goal. Patients who received orforglipron also reported weight loss — up to 16 pounds without","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/eli-lillys-weight-loss-pill-152045475.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["GB00BDT5M118.USD","LLY","LU1868836914.USD","SG9999018857.SGD","LU0354030438.USD","LU0256863902.USD","NVO","LU1127390331.HKD","IE0004445239.USD","RHHBY","03165","LU0882574139.USD","LU0006306889.USD","LU0114720955.EUR","LU2357305700.SGD","LU2750360641.GBP","CDC","LU1280957306.USD","LU1720051017.SGD","IE00B4R5TH58.HKD","SGXZ81514606.USD","LU0203201768.USD","LU0471298694.HKD","LU0823416689.USD","LU2237438978.USD","LU1551013342.USD","SG9999015952.SGD","IE00BKVL7J92.USD","SG9999014906.USD","LU0106261372.USD","IE00B2B36J28.USD","LU2750360997.AUD","LU0289739699.SGD","LU0122379950.USD","LU1868837300.USD","BK4588","LU1267930730.SGD","LU0456855351.SGD","LU1917777945.USD","LU2602419157.SGD","LU2237443549.SGD","LU2361045086.USD","LU1548497426.USD","LU0109391861.USD","LU2361044865.SGD","LU0466842654.USD","LU1366192091.USD","SG9999017495.SGD","LU0320765059.SGD","LU0820561909.HKD"],"gpt_icon":1},{"id":"2528474479","title":"Pharma Stock Roundup: J&J's Q1 Results, PFE's Obesity Setback","url":"https://stock-news.laohu8.com/highlight/detail?id=2528474479","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528474479?lang=en_us&edition=fundamental","pubTime":"2025-04-17 21:15","pubTimestamp":1744895700,"startTime":"0","endTime":"0","summary":"J&J JNJ began the earnings season for the drug and biotech sector this week. Pfizer PFE announced the discontinuation of its danuglipron weight loss pill program. The European Commission granted marketing authorization for the expanded use of Roche’s RHHBY cancer drug, Columvi. Sanofi SNY provided an update on its respiratory pipeline.Here's a recap of the week’s most important stories.J&J beat first-quarter estimates for both earnings and sales. Adjusted earnings of $2.77 per share rose 2.2% from the year-ago period. Sales of $21.89 billion rose 2.4% from the year-ago quarter. Innovative Medicines segment sales rose 2.3% year over year to $13.87 billion. MedTech segment sales came in at $8.02 billion, up 2.5% from the year-ago period.The U.S. Centers for Disease Control and Prevention’s  Advisory Committee on Immunization Practices recommended the expanded use of Pfizer and GSK’s respiratory syncytial virus  vaccines, Abrysvo and Arexvy, respectively, in adults aged 50 to 59 at increa","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pharma-stock-roundup-j-js-131500764.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0985320562.USD","IE00BBT3K403.USD","LU1032466523.USD","LU2347655156.SGD","BK4550","LU2129689605.HKD","LU2430703095.HKD","SG9999001176.USD","RHHBY","IE00BVYPNV92.GBP","BK4568","03165","SG9999013999.USD","SNY","LU0170899867.USD","LU1066051225.USD","LU0122379950.USD","LU1162221912.USD","LU1244550494.USD","PFE","IE00B19Z3B42.SGD","LU0985481810.HKD","LU0058720904.USD","LU0795875169.SGD","LU1244550221.USD","LU1778281490.HKD","IE00BFXG1179.USD","IE00B19Z3581.USD","JNJ","LU1066051811.HKD","LU2430703178.SGD","LU2505996509.AUD","SG9999003800.SGD","IE00BGHQF631.EUR","LU2430703251.USD","LU0792757196.USD","IE00BSNM7G36.USD","SG9999001440.SGD","IE00BFTCPJ56.SGD","LU0345769128.USD","LU1585245621.USD","SGXZ57979304.SGD","IE00BN8TJ469.HKD","IE0002141913.USD","LU0203345920.USD","LU0098860793.USD","LU1718418525.SGD","CDC","IE00BDGV0183.EUR","BK4581"],"gpt_icon":1}],"pageSize":4,"totalPage":50,"pageCount":1,"totalSize":200,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CDC\",params:#limit:5,,,undefined,":[{"date":"2025-04-10","symbol":"CDC","amount":0.22096,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-04-10","defaultRemindTime":1744291800000,"name":"VictoryShares US EQ Income Enhanced Volatility Wtd ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-04-11","payableDate":"2025-04-10","currency":"USD","dateTimestamp":1744257600000,"payDate":"2025-04-11"},{"date":"2025-03-10","symbol":"CDC","amount":0.20589,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-10","defaultRemindTime":1741613400000,"name":"VictoryShares US EQ Income Enhanced Volatility Wtd ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-11","payableDate":"2025-03-10","currency":"USD","dateTimestamp":1741579200000,"payDate":"2025-03-11"},{"date":"2025-02-07","symbol":"CDC","amount":0.133071,"announcedDate":"2025-02-06","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-02-07","defaultRemindTime":1738938600000,"name":"VictoryShares US EQ Income Enhanced Volatility Wtd ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-02-10","payableDate":"2025-02-07","currency":"USD","dateTimestamp":1738904400000,"payDate":"2025-02-10"},{"date":"2025-01-08","symbol":"CDC","amount":0.007166,"announcedDate":"2025-01-07","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-01-08","defaultRemindTime":1736346600000,"name":"VictoryShares US EQ Income Enhanced Volatility Wtd ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-01-09","payableDate":"2025-01-08","currency":"USD","dateTimestamp":1736312400000,"payDate":"2025-01-09"},{"date":"2024-12-12","symbol":"CDC","amount":0.414202,"announcedDate":"2024-12-11","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-12","defaultRemindTime":1734013800000,"name":"VictoryShares US EQ Income Enhanced Volatility Wtd ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-13","payableDate":"2024-12-12","currency":"USD","dateTimestamp":1733979600000,"payDate":"2024-12-13"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CDC\",market:\"US\",,,undefined,":[{"executeDate":"2015-04-21","recordDate":"2015-04-23","paymentDate":"2015-04-24","value":0.0278085,"currency":"USD"},{"executeDate":"2015-05-19","recordDate":"2015-05-21","paymentDate":"2015-05-22","value":0.1054201,"currency":"USD"},{"executeDate":"2015-06-16","recordDate":"2015-06-18","paymentDate":"2015-06-19","value":0.1094172,"currency":"USD"},{"executeDate":"2015-07-21","recordDate":"2015-07-23","paymentDate":"2015-07-24","value":0.0106339,"currency":"USD"},{"executeDate":"2015-08-18","recordDate":"2015-08-20","paymentDate":"2015-08-21","value":0.1070379,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CDC\",market:\"US\",delay:false,,,undefined,":{}}}